Efficacy of inactive bivalent and trivalent Streptococcus agalactiae bacteria (biotype 1 2) vaccines on tilapia, Oreochromis niloticus (original) (raw)
Related papers
Jurnal Akuakultur Indonesia
Streptococcus agalactiae is a major bacterial streptococcosis disease that infects tilapia. This study aimed to analyze a specific and nonspecific immune system in fry tilapia that has been given with S. agalactiae vaccine from N3M and N4M strain and examine the protective immunity against S. agalactiae N3M, N4M, N17O, NK1, and N14G strains infection. Fry tilapia used in this study has the weight of 7.086±0.948 g and length of 7.443±0.353 cm. The S. agalactiae strains that used were N3M, N4M, N17O, NK1, and N14G. Fry tilapia was vaccinated through intraperitoneal injection method with 0.1 mL per fish of N3M and N4M vaccines. Fish reared in aquarium sizing of 60×30×50 cm 3 with a density of 10 fishes/aquarium. Two weeks after vaccination, fry tilapia was tested with 0.1 mL/fish of each N3M, N4M, N17O, NK1, and N14G strains through intraperitoneal injection method. Antibody level measured with indirect enzym-linked immunosorbent assay (ELISA) method. The result of antibody level in vaccinated fish after vaccination of N3M, N4M vaccine, N3M and N4M control were 0.767; 0.743; 0.587; and 0.544, respectively. Relative percent survival in N3M vaccinated fish after challenged with N3M and N4M was 87.50% dan 64.70%, respectively, otherwise in N4M vaccinated fish was 62.50% dan 76.47%, respectively. N3M and N4M vaccine strain have better protection as only if it tested with similar bacteria strain.
2018
Tilapia (Oreochromis niloticus) is one of the most cultured species in the world. However, bacterial disease caused by Streptococcus spp. is one of the major problems affecting farmed tilapia worldwide. Hybrid red tilapia is highly susceptible to this disease and mortality may reach up to 70% within a week. Thus, the study was conducted to develop a recombinant vaccine of S. agalactiae, Millud II and S. iniae, TSK_2 previously isolated from infected tilapia. The isolates were successfully characterised as S. agalactiae and S. iniae respectively by species-specific PCR assay. The result confirms the amplification of 300 bp amplicons of 16S rRNA gene and sequence analysis demonstrated 98% similarity with complete genome of S. iniae, TSK_2 in BLASTn study. In addition, PCR amplification with primers specific for S. agalactiae 16S rRNA confirmed the target amplicons of 220 bp from positive control of bacterial DNA for S. agalactiae, Millud II. In order to analyse the antigenicity of S. ...
Vaccines, 2016
Streptococcus agalactiae is an emerging infectious disease adversely affecting Nile tilapia (Niloticus oreochromis) production in aquaculture. Research carried out in the last decade has focused on developing protective vaccines using different strategies, although no review has been carried out to evaluate the efficacy of these strategies. The purpose of this review is to provide a synopsis of vaccination strategies and antigen delivery systems currently used for S. agalactiae vaccines in tilapia. Furthermore, as shown herein, current vaccine designs include the use of replicative antigen delivery systems, such as attenuated virulent strains, heterologous vectors and DNA vaccines, while non-replicative vaccines include the inactivated whole cell (IWC) and subunit vaccines encoding different S. agalactiae immunogenic proteins. Intraperitoneal vaccination is the most widely used immunization strategy, although immersion, spray and oral vaccines have also been tried with variable succ...
2011
Streptococcus iniae infections are becoming an increasing problem in aquaculture and have been reported worldwide in a variety of fish species. Our previous study showed that S. iniae infection in tilapia Oreochromis sp. and Asian sea bass Lates calcarifer cause serious damage in fish farm in Thailand. To prevent streptococcosis caused by S. iniae, a formalinkilled vaccine was applied in red tilapia Oreochromis niloticus x O. mossambicus by injection, immersion and oral vaccination. At 1 week post vaccination, levels of antibody titer and some blood parameters response to different routes of administration were significantly different. The best disease resistance was found in the group injected with vaccine plus -(1,3/1,6)– glucan with the relative percent survival (RPS) of 95.12% followed by pure vaccine injection (RPS = 80.49%), immersion (RPS = 41.46%) and oral vaccination (RPS = 9.75%). No difference in blood parameters of tilapia after vaccination for 4 weeks was observed. How...
Background Streptococcosis and Motile Aeromonad Septicemia (MAS) are important diseases of tilapia, Oreochromis spp. and causes huge economic losses in aquaculture globally. The feed-based vaccination may be an alternative to minimize major infectious diseases in tilapia. Thus, this study aims to evaluate the haemato-immunological responses and effectiveness of a newly developed feed-based killed bivalent vaccine against Streptococcus iniae and Aeromonas hydrophila in hybrid red tilapia. A total of 495 hybrid red tilapia of 61.23±4.95 g were distributed into 5 groups (each with triplicate). The fish were immunized orally through bivalent (combined S. iniae and A. hydrophila ) spray vaccine (BS group), bivalent formulate vaccine (BF group), monovalent S. iniae vaccine (MS group), monovalent A. hydrophila vaccine (MA group) and unvaccinated as a control group. The vaccine was orally administered on days 0, 14 and 42 applied feed-based bacterin at 5% body weight. The blood and spleen s...
Fish & Shellfish Immunology, 2019
Streptococcus agalactiae species have been recognized as the main pathogen causing high mortality in fish leading to significant worldwide economical losses to the aquaculture industries. Vaccine development has become a priority in combating multidrug resistance in bacteria; however, there is a lack of commercial live attenuated vaccine (LAV) against S. agalactiae in Malaysia. The aim of this study is to compare two methods using attenuated bacteria as live vaccine and to evaluate the efficacy of selected LAV on the immune responses and resistance of Oreochromis niloticus (tilapia) against S. agalactiae. The LAV derived from S. agalactiae had been weakened using the chemical agent Acriflavine dye (LAV1), whereas the second vaccine was weakened using serial passages of bacteria on broth media (LAV2). Initial immunization was carried out only on day one, given twice-in the morning and evening, for the 42 day period. Serum samples were collected to determine the systemic antibody (IgM) responses and lysozymal (LSZ) activity using ELISA. On day 43 after immunization, the fish were injected intraperitoneally (i.p) with 0.1 mL of S. agalactiae at LD 50 = 1.5 × 10 5 (CFU)/ fish. Fish were monitored daily for 10 days. Clinical signs, mortality and the relative percent of survival (RPS) were recorded. Trial 1 results showed a significant increased (P<0.05) in serum IgM titers and LSZ activity as compared to LAV2 and the control group (unvaccinated fish). The efficacy of LAV1 was proven effective as determined by the RPS values, LAV1 at 81.58% as compared to LAV2 at 65.79%. Trial 2 of LAV1 and control group were further determined by administering primary and booster doses revealed a RPS value for LAV1 of 82.05%, with the significant enhancement on the immune responses of tilapia as compared to control group. In conclusion, LAV revealed to elevate antibody IgM levels, LSZ activity and provide long-term protection when added to feed. LAV is a low-cost vaccine shown to rapidly increase the immune response of fish and increase survival rates of fish against S. agalactiae infection.
Journal of Fish Diseases, 2002
Passive immunization of tilapia, Oreochromis niloticus, was conducted to determine whether anti‐Streptococcus iniae whole sera (ASI), heat inactivated anti‐S. iniae whole sera (HIASI) and normal whole sera (NWS) were protective when intraperitoneally (i.p.) injected into tilapia. The ASI was produced in tilapia actively immunized (challenged) with virulent S. iniae by i.p. injection. An antibody response against S. iniae was demonstrated by enzyme linked immunosorbent assay (ELISA) and 18% of the immunized fish died because of the S. iniae infection. The actively immunized tilapia demonstrated a secondary antibody response and immunity to S. iniae after challenge with S. iniae by i.p. injection. Survival was 100% in the actively immunized fish. The NWS was obtained from tilapia free of ASI antibody and susceptible to S. iniae infection (40% mortality). In two separate experiments, significantly higher mortality was noted in tilapia passively immunized with NWS (33 and 53%) and phosp...
BMC Veterinary Research
Background: Streptococcosis and Motile Aeromonad Septicemia (MAS) are important diseases of tilapia, Oreochromis spp. and causes huge economic losses in aquaculture globally. The feed-based vaccination may be an alternative to minimize major infectious diseases in tilapia. Thus, this study aims to evaluate the haemato-immunological responses and effectiveness of a newly developed feed-based killed bivalent vaccine against Streptococcus iniae and Aeromonas hydrophila in hybrid red tilapia. A total of 495 hybrid red tilapia of 61.23 ± 4.95 g were distributed into 5 groups (each with triplicate). The fish were immunized orally through bivalent (combined S. iniae and A. hydrophila) spray vaccine (BS group), bivalent formulate vaccine (BF group), monovalent S. iniae vaccine (MS group), monovalent A. hydrophila vaccine (MA group) and unvaccinated as a control group. The vaccine was orally administered on days 0, 14 and 42 applied feed-based bacterin at 5% body weight. The blood and spleen samples were collected from all groups on 7, 21 and 49 days post-vaccination, and also 96 h post-infection to assess their haemato-immune responses.
E3S Web of Conferences, 2021
Alternative prevention should be developed to control disease outbreaks in Tilapia culture caused by co-infections of Aeromonas hydrophila and Streptococcus agalactiae. Applications of vaccines with low cost and simple methods are highly recommended. This study was conducted to find out the safety and the efficacy of immersion vaccine in Tilapia used bivalent vaccines with formalin inactivated of S. agalactiae and A. hydrophila. Tilapia (Oreochromis niloticus) were divided into two groups, vaccinated and not vaccinated, with single and double doses immersion. The results showed that single and double doses of immersion vaccine were safe for fish (SR 100%) and effectively increased the antibody titer values compared to non-vaccinated fish. The immersion vaccine method can be recommended as an alternative to controlled fish diseases, especially for both Motile Aeromonads Septicaemia and Streptococcosis caused by A. hydrophila and S. agalactiae infections, respectively.
Evaluation on the Pathogenesis of Streptococcus agalactiae in Nile Tilapia (Oreochromis niloticus)
Brazilian Archives of Biology and Technology, 2010
The pathogenesis of a Streptococcus agalactiae was evaluated in a three-period experiment. Two groups of 40 fishes were intraperitoneally (i.p.) challenged in each experimental period with different infective doses of the pathogen. Doses varied from 1.0 x 10(6) to 1.5 x 10(8) CFU/fish. One group of 40 tilapia i.p. injected with tryptic soy broth (TSB) was used as a control group in each period. Mortalities varied from 67.5% in group 8 (infective dose 1.0 x 10(6) CFU/fish) to 90.0% in group 1 (infective dose 1.5 x 10(8) CFU/fish). Significant differences in mortalities were found only between group 8 and each of the other groups, except group 5 (infective dose 6.0 x 10(6) CFU/fish; mortality 75.0%). The highest mortality coefficients were observed in days 1-2 after inoculation (accumulated mortality 44.4%), and a second peak of mortality occurred at days 6-7. Challenged fishes from all the groups showed alterations in behaviour and similar clinical signs. These were anorexia, letharg...